Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ESSA Pharma Inc EPIX

Healthcare Biotechnology
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a... see more

Recent & Breaking News (NDAQ:EPIX)

ESSA Pharma Inc. Announces Share Consolidation

Canada NewsWire April 19, 2018

ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders

Canada NewsWire March 28, 2018

31 Stocks Moving In Monday's Mid-Day Session

Benzinga.com  March 26, 2018

ESSA Pharma Approves Stock Option Plan, RSU Plan, and Option Grants

Canada NewsWire February 23, 2018

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2017

Canada NewsWire February 13, 2018

ESSA to Present at Noble Capital Markets' NobleCon14

Canada NewsWire January 26, 2018

ESSA Announces Management Team Change

Canada NewsWire January 25, 2018

ESSA expects 180-day extension to regain compliance with the Nasdaq Bid Price Rule

Canada NewsWire January 16, 2018

ESSA Completes Second Tranche of Equity Offering, Raising Additional US$5 Million

Canada NewsWire January 16, 2018

ESSA Completes US$21 Million Equity Offering

Canada NewsWire January 9, 2018

ESSA announces filing of second amended and restated prospectus supplement and an update to previously announced equity offering

Canada NewsWire January 5, 2018

ESSA Announces Filing of Amended and Restated Prospectus Supplement and an Update to Previously Announced Equity Offering

Canada NewsWire January 2, 2018

ESSA Announces Filing of Prospectus Supplement and an Update to Previously Announced Equity Offering

Canada NewsWire December 15, 2017

CORRECTION FROM SOURCE: IIROC Trade Resumption - ESSA Pharma Inc.

Newsfile December 13, 2017

IIROC Trading Resumption - EPI

Canada NewsWire December 13, 2017

IIROC Trade Resumption - ESSA Pharma Inc.

Newsfile December 13, 2017

ESSA Pharma Announces Pricing of Previously Announced Equity Offering

PR Newswire December 13, 2017

IIROC Trading Halt - EPI

Canada NewsWire December 13, 2017

IIROC Trade Halt - ESSA Pharma Inc.

Newsfile December 13, 2017

ESSA Pharma Announces Overnight Marketed Equity Offering

PR Newswire December 12, 2017